Hedge funds are buying these two big tech stocks while selling two rivals
Investing.com - UBS has upgraded Insulet Corporation (NASDAQ:PODD) from Neutral to Buy and raised its price target to $400.00 from $355.00. The stock currently trades at $333.47, with analysts broadly sharing UBS’s bullish stance as reflected in the strong buy consensus recommendation.
The upgrade reflects UBS’s increased conviction in Insulet’s growth trajectory, particularly regarding the company’s expansion into the Type 2 diabetes market. This optimism aligns with the company’s impressive 27.11% revenue growth over the last twelve months.
UBS believes Insulet’s Type 2 diabetes business ramp-up will be substantial enough to counterbalance an evolving competitive landscape where other companies may launch patch pumps or increase pharmacy access—areas that have historically been competitive advantages for Insulet.
Based on multiple key opinion leader checks, UBS has raised its 2025-2028 sales growth compound annual growth rate (CAGR) forecast for Insulet to 17% from just under 16% previously, aligning with consensus estimates.
The investment firm cited the "sheer upside opportunity" from Insulet’s ongoing Type 2 diabetes market expansion over the next 12-24 months as a key factor in its upgraded outlook.
In other recent news, Insulet Corporation reported impressive third-quarter earnings for 2025, surpassing Wall Street expectations. The company achieved an earnings per share of $1.24, outpacing the forecasted $1.14, which represents an 8.77% surprise. Insulet’s revenue reached $706.3 million, exceeding the consensus estimate of $678 million and reflecting a 29.9% year-over-year growth. U.S. Omnipod revenue contributed $497.1 million, marking a 25.6% increase, while international Omnipod revenue grew to $202.1 million, a 39.9% rise in constant currency. Jefferies responded to these strong results by raising its price target for Insulet to $400 from $375, maintaining a Buy rating. Similarly, BTIG reiterated its Buy rating with a $370 price target after the company’s robust performance. These developments highlight Insulet’s significant growth and positive analyst sentiment following the recent earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.